Soundscape descriptors and a conceptual framework for developing predictive soundscape models

Soundscape exists through human perception of the acoustic environment. This paper investigates how soundscape currently is assessed and measured. It reviews and analyzes the main soundscape descriptors in the soundscape literature, and provides a conceptual framework for developing predictive models in soundscape studies. A predictive soundscape model provides a means of predicting the value of a soundscape descriptor, and the blueprint for how to design soundscape. It is the key for implementing the soundscape approach in urban planning and design. The challenge is to select the appropriate soundscape descriptor and to identify its predictors. The majority of available soundscape descriptors are converging towards a 2-dimensional soundscape model of perceived affective quality (e.g., Pleasantness–Eventfulness, or Calmness–Vibrancy). A third potential dimension is the appropriateness of a soundscape to a place. This dimensions provides complementary information beyond the perceived affective quality. However, it depends largely on context, and because a soundscape may be appropriate to a place although it is poor, this descriptor must probably not be used on its own. With regards to predictors, or soundscape indicators, perceived properties of the acoustic environment (e.g., perceived sound sources) are winning over established acoustic and psychoacoustic metrics. To move this area forward it is necessary that the international soundscape community comes together and agrees on relevant soundscape descriptors. This includes to agree on numerical scales and assessment procedures, as well as to standardize them

Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target Antigens

Epstein–Barr virus (EBV) was discovered in 1964 in the cell line of Burkitt lymphoma and became first known human oncogenic virus. EBV belongs to the Herpesviridae family, and is present worldwide as it infects 95% of people. Infection with EBV usually happens during childhood when it remains asymptomatic; however, in adults, it can cause an acute infection known as infectious mononucleosis. In addition, EBV can cause wide range of tumors with origins in B lymphocytes, T lymphocytes, and NK cells. Its oncogenicity and wide distribution indicated the need for vaccine development. Research on mice and cultured cells as well as human clinical trials have been in progress for a few decades for both prophylactic and therapeutic EBV vaccines. The main targets of the vaccines are EBV envelope glycoproteins such as gp350 and EBV latent genes. The long wait for the EBV vaccine is due to the complexity of the EBV replication cycle and the wide range of its host cells. Although some strategies such as the use of dendritic cells and recombinant Vaccinia viral vectors have shown success, ongoing clinical trials using mRNA-based vaccines as well as new delivery systems as nanoparticles are yet to show the best choice of vaccine target and its production strategy

Role of TLRs in HIV-1 Infection and Potential of TLR Agonists in HIV-1 Vaccine Development and Treatment Strategies

Toll-like receptors (TLRs), as a family of pattern recognition receptors, play an important role in the recognition of HIV-1 molecular structures by various cells of the innate immune system, but also provide a functional association with subsequent mechanisms of adaptive immunity. TLR7 and TLR8 play a particularly important role in the innate immune response to RNA viruses due to their ability to recognise GU-rich single-stranded RNA molecules and subsequently activate intracellular signalling pathways resulting in expression of genes coding for various biological response modifiers (interferons, proinflammatory cytokines, chemokines). The aim of this review is to summarise the most recent knowledge on the role of TLRs in the innate immune response to HIV-1 and the role of TLR gene polymorphisms in the biology and in the clinical aspects of HIV infections. In addition, the role of TLR agonists as latency reversing agents in research to treat HIV infections and as immunomodulators in HIV vaccine research will be discussed

Methodology for development of airborne sound insulation descriptor valid for light-weight and masonry walls

status: Published onlin